Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 357

1.

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group..

JAMA. 2002 Nov 20;288(19):2421-31. Erratum in: JAMA. 2006 Jun 21;295(23):2726.

PMID:
12435255
2.

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group..

JAMA. 2001 Jun 6;285(21):2719-28.

PMID:
11386927
3.

Blood pressure control, drug therapy, and kidney disease.

Contreras G, Greene T, Agodoa LY, Cheek D, Junco G, Dowie D, Lash J, Lipkowitz M, Miller ER 3rd, Ojo A, Sika M, Wilkening B, Toto RD; African American Study of Kidney Disease and Hypertension Study Group Investigators..

Hypertension. 2005 Jul;46(1):44-50.

4.

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.

Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL.

Arch Intern Med. 2005 Apr 25;165(8):947-53.

PMID:
15851648
5.

Lessons from the African-American Study of Kidney Disease and Hypertension: an update.

Toto RD.

Curr Hypertens Rep. 2006 Oct;8(5):409-12. Review.

PMID:
16965728
6.

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.

Arch Intern Med. 2005 Apr 25;165(8):936-46.

PMID:
15851647
7.

Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.

Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J; AASK Study Group..

Am J Kidney Dis. 2006 Nov;48(5):739-51.

PMID:
17059993
8.
9.

Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.

Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD.

Nephrol Dial Transplant. 2008 Feb;23(2):573-9.

11.

Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial.

Davis EM, Appel LJ, Wang X, Greene T, Astor BC, Rahman M, Toto R, Lipkowitz MS, Pogue VA, Wright JT Jr; African American Study of Kidney Disease and Hypertension Research Collaborative Group..

Hypertension. 2011 Jun;57(6):1061-8. doi: 10.1161/HYPERTENSIONAHA.111.169367.

12.

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial..

JAMA. 2002 Dec 18;288(23):2981-97. Erratum in: JAMA. 2004 May 12;291(18):2196. JAMA 2003 Jan 8;289(2):178.

PMID:
12479763
13.

Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.

Thornley-Brown D, Wang X, Wright JT Jr, Randall OS, Miller ER, Lash JP, Gassman J, Contreras G, Appel LJ, Agodoa LY, Cheek D.

Arch Intern Med. 2006 Apr 10;166(7):797-805.

PMID:
16606818
14.

Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).

Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, Douglas J, Jamerson K, Lewis J, Kutner M, Randall OS, Wang SR.

J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S154-65.

15.

An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.

Miranda RD, Mion D Jr, Rocha JC, Kohlmann O Jr, Gomes MA, Saraiva JF, Amodeo C, Filho BL.

Clin Ther. 2008 Sep;30(9):1618-28. doi: 10.1016/j.clinthera.2008.09.008.

PMID:
18840367
16.

Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.

Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin S, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T; ALLHAT Collaborative Research Group..

Ann Intern Med. 2006 Feb 7;144(3):172-80.

PMID:
16461961
17.

Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.

Appel LJ, Wright JT Jr, Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY; African American Study of Kidney Disease and Hypertension Collaborative Research Group..

Arch Intern Med. 2008 Apr 28;168(8):832-9. doi: 10.1001/archinte.168.8.832.

18.

Antihypertensive drugs and renal protection.

Fukuda M, Usami T, Yoshida A, Kimura G.

JAMA. 2003 Mar 5;289(9):1102-3; author reply 1103. No abstract available.

PMID:
12622571
19.

Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients.

Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, Fioretto P, Nosadini R.

Diabetes. 1996 Feb;45(2):216-22.

PMID:
8549868
Items per page

Supplemental Content

Support Center